- Home
- BHC vs HRMY Comparison
BHC vs HRMY Comparison
Compare BHC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- HRMY
- Stock Information
- Founded
- BHC N/A
- HRMY 2017
- Country
- BHC Canada
- HRMY United States
- Employees
- BHC N/A
- HRMY N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- BHC Health Care
- HRMY Health Care
- Exchange
- BHC Nasdaq
- HRMY Nasdaq
- Market Cap
- BHC 2.2B
- HRMY 2.0B
- IPO Year
- BHC N/A
- HRMY 2020
- Fundamental
- Price
- BHC $6.24
- HRMY $35.68
- Analyst Decision
- BHC Hold
- HRMY Strong Buy
- Analyst Count
- BHC 2
- HRMY 9
- Target Price
- BHC $9.00
- HRMY $50.56
- AVG Volume (30 Days)
- BHC 2.9M
- HRMY 942.2K
- Earning Date
- BHC 10-29-2025
- HRMY 11-04-2025
- Dividend Yield
- BHC N/A
- HRMY N/A
- EPS Growth
- BHC N/A
- HRMY 50.44
- EPS
- BHC 0.97
- HRMY 3.17
- Revenue
- BHC $10,029,000,000.00
- HRMY $825,944,000.00
- Revenue This Year
- BHC $6.81
- HRMY $20.68
- Revenue Next Year
- BHC $4.11
- HRMY $15.93
- P/E Ratio
- BHC $6.47
- HRMY $11.16
- Revenue Growth
- BHC 5.86
- HRMY 21.13
- 52 Week Low
- BHC $4.25
- HRMY $25.52
- 52 Week High
- BHC $8.69
- HRMY $40.93
- Technical
- Relative Strength Index (RSI)
- BHC 47.14
- HRMY 74.97
- Support Level
- BHC $5.91
- HRMY $32.77
- Resistance Level
- BHC $6.15
- HRMY $36.20
- Average True Range (ATR)
- BHC 0.25
- HRMY 1.18
- MACD
- BHC -0.03
- HRMY 0.23
- Stochastic Oscillator
- BHC 32.55
- HRMY 90.45
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.